Imavist chosen for major prostate cancer trial
This article was originally published in Clinica
Executive Summary
Alliance Pharmaceutical says that its Imavist imaging agent has been selected for use in a major clinical trial in the US to determine whether contrast-enhanced ultrasound imaging can improve prostate cancer detection.